Akorn (NASDAQ:AKRX) saw its share price trade relatively negative in the recent trading session. The share price was last updated to $28.75 with a loss of -0.26 points or -0.9%. The net money flow was $2.83 million and the up/down ratio was 1.56. Approximately $7.92 million was the inflow in upticks and $5.09 million was the outflow in downticks. On a weekly measure, the shares have seen a price change of -0.59%.The shares witnessed a block transaction with a net money flow of $3.09 million. The total money in uptick was $3.09 million and in downtick was $0 million with the up/down ratio reaching 0.
The stock has recorded a 20-day Moving Average of 5.31% and the 50-Day Moving Average is 2.65%. The company shares have dropped 37.21% in the past 52 Weeks. On June 23, 2015 The shares registered one year high of $48.5 and one year low was seen on March 18, 2016 at $17.57. The 50-day moving average is $28.75 and the 200 day moving average is recorded at $28.2. S&P 500 has rallied 1.93% during the last 52-weeks.
Akorn (NASDAQ:AKRX): The stock opened at $29.16 on Tuesday but the bulls could not build on the opening and the stock topped out at $29.22 for the day. The stock traded down to $28.00 during the day, due to lack of any buying support eventually closed down at $28.75 with a loss of -0.90% for the day. The stock had closed at $29.01 on the previous day. The total traded volume was 1,233,071 shares.
Currently the company Insiders own 30.1% of Akorn shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -9.1% . Institutional Investors own 80.4% of Akorn shares. During last six month period, the net percent change held by insiders has seen a change of -9.1%. On the companys insider trading activities, Bonaccorsi Joseph, officer (Sr VP Gen Counsel & Secretary) of Akorn Inc, unloaded 6,500 shares at an average price of $29.84 on June 14, 2016. The total amount of the transaction was worth $193,960, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.
Akorn Inc. (Akorn), together with its wholly owned subsidiaries, is a specialty pharmaceutical company that develops, manufactures and markets generic and branded prescription pharmaceuticals, as well as animal and over-the-counter (OTC) consumer health products. The Company specializes in sterile and non-sterile dosage forms, including ophthalmics, injectables, oral liquids, otics, topicals, inhalants and nasal sprays. The Company operates in two segments: Prescription Pharmaceuticals, which is engaged in the sale of branded and generic prescription pharmaceuticals, and Consumer Health, which is engaged in the sale of branded and private label consumer and animal health products. The Company operates pharmaceutical manufacturing facilities in Decatur, Illinois; Somerset, New Jersey; Amityville, New York, and Paonta Sahib, Himachal Pradesh, India, as well as a central distribution warehouse in Gurnee, Illinois, and an additional warehousing facility in Amityville, New York.